Common questions about Symmetrel (FAQ)
Q: How quickly should I expect to notice any effects from Symmetrel?
Official product information indicates that the time it takes to observe the effects of Symmetrel can vary depending on the condition being addressed. For certain uses, clinical experience suggests that initial effects may begin to be apparent within approximately two weeks of starting the medicine, but this timeline is not definitive for everyone.
Q: Do the side effects of Symmetrel go away over time?
Regulatory documents note that many central nervous system (CNS) undesirable effects, such as dizziness or nervousness, are often described as transient, meaning they may lessen or disappear shortly after treatment begins. However, this pattern may not apply to all potential side effects, and any persistent or new effects should be noted.
Q: Is it normal to feel anxious or have trouble sleeping when starting Symmetrel?
Official regulatory documents list trouble sleeping (insomnia) as a common undesirable effect associated with Symmetrel. Additionally, anxiety is documented as a symptom that may be new or increased and warrants attention during use, according to official product information.
Q: What should I do if I experience dizziness while taking Symmetrel?
The potential for dizziness and lightheadedness is noted in regulatory profiles as a common effect. Regulatory documents state that patients are sometimes advised to sit or lie down until the feeling passes. Additionally, rising slowly from a sitting or lying position is often mentioned as a general measure to help manage this effect.
Q: Can I crush or open the Symmetrel capsules?
For the immediate-release (IR) forms, capsules and tablets are typically required to be swallowed whole and not crushed or chewed. This requirement relates to the drug's designed release properties. Specific extended-release (ER) forms may have different administration instructions, but this must be confirmed with the prescribed product’s official label.
Q: What are the signs of taking too much Symmetrel?
Acute overdose of Symmetrel has been associated with signs requiring immediate attention. These documented signs can include agitation, visual hallucinations, delirium, seizures, and heart rhythm changes (arrhythmias). Official safety information documents the potential for these severe effects and notes that immediate attention is required.
Q: Does Symmetrel change how other medicines are absorbed in the body?
The official regulatory profile primarily documents interactions related to clearance (how the drug is eliminated by the kidneys) and additive effects on the nervous system. Interference with the absorption (uptake) of other medicines is generally not the primary mechanism of interaction described in the official product information.
Q: What is the longest period of time people typically use Symmetrel?
The duration of use for Symmetrel is dependent on the medical condition it is addressing. While treatment for influenza may be very short-term, the medication is sometimes prescribed for long-term use (e.g., six months or longer) in the context of certain chronic conditions.
Q: Is Symmetrel a habit-forming medicine?
Symmetrel is not classified as a federally controlled substance in the United States. However, official drug labels do require monitoring for certain impulse control or compulsive behaviors (such as intense urges to gamble or increased sexual urges) that have been reported with its use.
Q: What is the difference between Symmetrel and other similar-sounding antivirals?
Symmetrel (Amantadine) is chemically related to the antiviral medicine Rimantadine, and both interfere with the Influenza A virus. Official reports note that Amantadine is generally associated with a higher incidence of central nervous system (CNS) reactions than Rimantadine.
Q: Is Symmetrel effective against all types of influenza (flu)?
No. The drug is only indicated and demonstrated to be active against Influenza A viruses. Official regulatory information confirms that Symmetrel is not effective against the Influenza B virus.
Q: Is Symmetrel a type of dopamine agonist?
Yes, according to official classification, Symmetrel is defined as an indirect dopamine agonist. This means its mechanism involves modulating the activity of the chemical messenger dopamine in the brain, supporting its function without directly activating the receptor.
Q: Does Symmetrel affect the brain's chemicals?
Yes. The official information on how the medicine works documents that it affects the activity of key brain chemicals, specifically dopamine and glutamate, which contributes to its influence on movement and signaling.
Q: Is it necessary to have routine blood tests while using Symmetrel?
Routine blood tests are not described as mandatory for all patients. However, the official label strongly advises that plasma drug concentrations and renal function (kidney health) should ideally be monitored, particularly for patients with impaired kidney function or those taking certain interacting medicines.
Q: Can Symmetrel cause changes in mood or confusion?
Yes, official regulatory documents note the potential for central nervous system effects, including confusion and changes in mood. The label also documents the risk of suicidal thoughts or actions, necessitating close monitoring for these effects.
Q: Can Symmetrel be taken on an empty stomach?
Immediate-release (IR) forms are generally recommended to be taken with food to help reduce the possibility of stomach irritation. While some official patient information states the medicine can be taken at any time in relation to food, the recommendation to take it with food is often cited to improve digestive tolerance.
Q: Is Symmetrel a controlled substance?
No. Official governmental classifications confirm that Symmetrel (Amantadine) is not classified as a federally controlled substance in the United States.
Q: Is it possible to develop tolerance to Symmetrel over time?
Clinical reports regarding the drug's use for certain movement issues suggest that tolerance to the therapeutic effect may develop over a period of weeks or months. This suggests that the observed benefit may lessen after prolonged use.
